Platinum-based drugs in cancer therapy
Author(s)
Bibliographic Information
Platinum-based drugs in cancer therapy
（Cancer drug discovery and development）
Humana Press, c2000
- pbk
Available at 3 libraries
Note
Includes bibliographical references and index
Description and Table of Contents
Description
Leading international experts comprehensively review all aspects of platinum anticancer drugs and their current use in treatment, as well as examining their future therapeutic prospects. Writing from a variety of disciplines, these authorities discuss the chemistry of cisplatin in aqueous solution, the molecular interaction of platinum drugs with DNA, and such exciting new areas as DNA mismatch repair and replicative bypass, apoptosis, and the transport of platinum drugs into tumor cells. The emergent platinum drugs of the future-orally active agents, the sterically hindered ZD0473, and the polynuclear charged platinum BBR3464-are also fully considered. Timely and interdisciplinary, Platinum-Based Drugs in Cancer Therapy offers cancer therapeutics specialists an illuminating survey of every aspect of platinum drugs from mechanisms of action to toxicology, tumor resistance, and new analogs.
Table of Contents
Part I: Platinum Chemistry. The Chemistry of Cisplatin in Aqueous Solution, Susan J. Berners-Price and Trevor G. Appleton. Chemistry and Structural Biology of 1,2-Interstrand Adducts of Cisplatin, Viktor Brabec. Transplatin-Modified Oligonucleotides as Potential Antitumor Drugs, Marc Leng, Annie Schwartz, and Marie-Josephe Giraud-Panis. Part II: Platinum Biochemistry. Cisplatin Accumulation, Paul A. Andrews. Cisplatin Resistance in Ovarian Cancer: Mismatch Repair and Engagement of Apoptosis, Robert Brown. DNA Adduct Tolerance and Bypass, Stephen G. Chaney and Alexandra Vaisman. How Does Cisplatin Kill Cells? Daniel Fink and Stephen B. Howell. Part III: Clinical Antitumor Activity and Toxicology of Platinum Drugs. Clinical Experience with Cisplatin and Carboplatin, M. S. Highley and A. H. Calvert. Clinical Experience: Platinum and Taxanes, Michelle Vaughan, Francisco Sapunar, and Martin Gore. Clinical Experience: DACH-Based Platinum Drugs, Peter J. O'Dwyer, James P. Stevenson, and Steven W. Johnson. Clinical Toxicology of Platinum-Based Cancer Chemotherapeutic Agents, Mark J. McKeage. Toxicology and Regulatory Aspects of Platinum Drugs, Diana L. Clark, Paul A. Andrews, D. D. Smith, Joseph J. DeGeorge, Robert L. Justice, and Julie G. Beitz. Part IV: New Platinum Drugs of the Future. New Platinum Drugs: The Pathway to Oral Therapy, Lloyd R. Kelland. Polynuclear Charged Platinum Compounds as a New Class of Anticancer Agents: Toward a New Paradigm, Nicholas Farrell. Index.
by "Nielsen BookData"